Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.59 |
| ▸ | PPARA | Q07869 | 19/20 | 0.59 |
| ▸ | PPARD | Q03181 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13847872 | 0.85 | PPARG (0.46) | PPARGPPARAPPARD | |
| SCHEMBL5758732 | 0.84 | PPARG (0.60) | PPARGPPARAPPARD | |
| SCHEMBL5761790 | 0.83 | PPARG (0.62) | PPARGPPARAPPARD | |
| SCHEMBL5741098 | 0.82 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL5759675 | 0.81 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL6432402 | 0.81 | PPARG (0.72) | PPARGPPARAPPARD | |
| SCHEMBL5042459 | 0.80 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL5761883 | 0.80 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL5761277 | 0.79 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL5760189 | 0.79 | PPARG (0.56) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1078923-B1 | Process for the preparation of benzothiophene derivatives | HOFFMANN LA ROCHE (CH) | 2006-03-08 | — | — | EP | claimed |
| EP-1282619-B1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | claimed |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2004-02-05 | — | — | US | claimed |
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2003-05-15 | — | — | US | claimed |
| EP-1282619-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | claimed |
| US-6437144-B2 | CYCLOCARBONYLATION | HOFFMANN-LA ROCHE INC. | 2002-08-20 | — | — | US | claimed |
| US-20020010345-A1 | Methods for the preparation of 4-hydroxy benzothiophene | JUNGHANS BERND (DE) | 2002-01-24 | — | — | US | claimed |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | HOFFMANN-LA ROCHE INC. | 2001-12-06 | — | — | US | claimed |
| WO-2001079202-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-25 | — | — | WO | claimed |
| EP-1078923-A2 | Process for the preparation of benzothiophene derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-28 | — | — | EP | claimed |
| EP-1078923-B1 | Process for the preparation of benzothiophene derivatives | HOFFMANN LA ROCHE (CH) | 2006-03-08 | — | — | EP | disclosed |
| EP-1282619-B1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-6753432-B2 | BROMOMETHYLATION OR CHLOROMETHYLATION; CONDENSATION WITH PRIMARY AMIDE; DEESTERIFICATION, SULFONATION | HOFFMANN-LA ROCHE INC. | 2004-06-22 | — | — | US | disclosed |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2004-02-05 | — | — | US | disclosed |
| US-6620941-B2 | Bromination of ethyl 3-oxovalerate, condensing with benzamide, then reducing with diisobutylaluminum hydride and sulfonating to form 2-(5-Methyl-2- phenyl-4-oxazolyl)ethanomethanesulfonic ester, used as chemical intermediates | HOFFMANN-LA ROCHE INC. | 2003-09-16 | — | — | US | disclosed |
| US-6291685-B1 | REACTING 1-(2-THIENYL)ALLYL DERIVATIVE IN SOLVENT MEDIUM CONTAINING BASE AND CARBOXYLIC ACID ANHYDRIDE WITH CARBON MONOXIDE IN PRESENCE OF CARBONYLATION CATALYST TO FORM ESTER COMPOUND; SAPONIFICATION TO FORM 4-HYDROXYBENZOTHIOPHENE | HOFFMANN-LA ROCHE INC. | 2001-09-18 | — | — | US | disclosed |
| EP-1078923-A2 | Process for the preparation of benzothiophene derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-28 | — | — | EP | disclosed |
| US-5599826-A | ANTIDIABETIC AGENT | BOEHRINGER MANNHEIM GMBH (DE) | 1997-02-04 | — | — | US | disclosed |
| EP-0700397-A1 | NEW THIAZOLIDINDIONES AND DRUGS CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1996-03-13 | — | — | EP | disclosed |
| WO-1994027995-A1 | NEW THIAZOLIDINDIONES AND DRUGS CONTAINING THEM | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | PPARG 80/4885PPARA 182/4885PPARD 45/4885 |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | PPARG 80/4885PPARA 182/4885PPARD 45/4885 |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | PPARG 80/4885PPARA 182/4885PPARD 45/4885 |
| US-20020010345-A1 | Methods for the preparation of 4-hydroxy benzothiophene | SLC5A2, TST, SLC5A1 | PPARG 677/4885PPARA 1335/4885PPARD 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.